ArticleActa bio-medica : Atenei Parmensis2021
Epidemiology of Toscana Virus in Italy (2018-2020), a summary of available evidences.
Article in Acta bio-medica : Atenei Parmensis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- (Re-)Emergence of Oropouche Virus (OROV) Infections: Systematic Review and Meta-Analysis of Observational Studies.Viruses · 2024Pooled it
- Article
- Clinical review of Toscana virus: a Mediterranean Neuroinvasive Phlebovirus.Frontiers in epidemiology · 2026Review
- Urine: A Pitfall for Molecular Detection of Toscana Virus? An Analytical Proof-of-Concept Study.Viruses · 2024Article
- Article
- Epidemiology, Isolation, and Genetic Characterization of Toscana Virus in Algerian Patients Displaying Neurological Infection, 2016-2018.IJID regions · 2023Article
- Review
- Toscana Virus Meningoencephalitis in Upper Bavaria.Deutsches Arzteblatt international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sir, Toscana Virus (TosV) is an arthropod-borne negative-stradend RNA virus belonging to the order of Bunyavirales, family of Phenuiviridae [1,2]. Originally isolated in 1971 in Tuscany, TosV is highly prevalent in countries bordering the northern shores of Mediterranean basin, mirroring the ecology of competent vectors (i.e. genera Phelebotomus and Sergentomyia) [1-6]. For instance, available reports from Italian regions of Piemonte, Emilia Romagna, Tuscany, Umbria, Puglia, Sicily and Sardinia have reported a prevalence for specific IgG antibodies ranging from 1.0% to 41.9% among healthy residents, and even more higher in some occupational groups (e.g. agricultural and forestry workers) [3-6]. While it is quite obvious that most of incident cases occur as pauci-symptomatic, the relatively high occurrence of IgM antibodies among patients complaining neurological symptoms (ranging between 4.7% to 27.2%) from the same areas suggests that a limited share of cases may develop a far more severe disorder [1,5]. Because of its potential epidemiological significance, since 2018 Italian National Health Service has included TosV neuroinvasive infections in the special surveillance for human arboviral infections, with periodic bulletins (https://www.epicentro.iss.it/arbovirosi/bollettini), whose content is subsequently summarized and discussed. Overall (Table 1), 182 cases of neuroinvasive TosV infections have been reported since 2018, with a case fatality ratio of 0.05%. Crude Incidence Rate was estimated in 0.101 cases per 100,000 (95% Confidence Interval [95%CI] 0.087-0.117), with an age-adjusted Incidence Rate (AIR) equals to 0.100 per 100,000, 95%CI 0.001-0.212. AIR were also heterogenous across the timeframe 2018-2020, being greater in 2018 (0.149 per 100,000), and then decreasing in the following years (0.093 and 0.060 for 2019 and 2020, respectively), while the majority of neuro-invasive TosV cases consistently occured during the months of August (38.5%), July (28.0%), and September (20.3%). Such a trend mirrored that of other arboviruses, and particularly West Nile Virus (WNV), that has been explained through the ecology of the vector [7,8]. Similarly to mosquitoes, intense warmth followed by precipitation deficits stimulate the replication of Phlebotomine, whose circulation is therefore particularly intense between July and September [9]. Unsurprisingly, 2018 was a record-breaking climate outlier in terms of summer temperatures, humidity, and lack of precipitation, that conversely were particularly intense during spring, and also Phlebotomine experienced an unprecedent thriving [1,9]. The role of the competent vector may also explain the increased risk for neuro-invasive TosV infections among males (70.3% of total cases) compared to females (Risk Ratio 2.498, 95%CI 1.817-3.434) (Table 2), as they are more commonly involved in outdoor activities (e.g. agriculture, forestry, and construction industries), particularly in the evening, at the peak of phlebotomine circulation [1,4]. On the contrary, despite the majority of incident cases occurred among and in subjects aged 0 to 39 years (38.5%), age groups 40 to 59 years-old and ≥ 60 years-old scored a risk for developing neuro-invasive infection similar to that of younger subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.